FGFR2 and melanoma: A new variant of FGFR2 with a mutation leading to Gly542Glu was reported in BRAFV600E melanoma patient during ongoing treatment with dabrafenib, a BRAFV600E inhibitor, as an example of intratumor clonal evolution resulting in the development of resistance [148].